Paper36980625
Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease.
Halperin R and 1 other. Cancers (Basel), 2023. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease. Papers, record 36980625. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36980625
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | Background |
Source ClinicalTrials.gov
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31368132 | Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. | Clin Genet | 2019 | https://conductscience.org/library/papers/31368132 | PubMed |
| 2 | 30714538 | Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours. | Curr Radiopharm | 2019 | https://conductscience.org/library/papers/30714538 | PubMed |
| 3 | 25956795 | Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25956795 | PubMed |
| 4 | 23392213 | Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. | Eur J Endocrinol | 2013 | https://conductscience.org/library/papers/23392213 | PubMed |
| 5 | 31392045 | The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. | J Gastrointest Oncol | 2019 | https://conductscience.org/library/papers/31392045 | PubMed |
| 6 | 27030075 | Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. | Nat Rev Clin Oncol | 2016 | https://conductscience.org/library/papers/27030075 | PubMed |
| 7 | 31737565 | The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients. | Front Oncol | 2019 | https://conductscience.org/library/papers/31737565 | PubMed |
| 8 | 28448665 | Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28448665 | PubMed |
| 9 | 33737209 | Impact of Pancreatic Neuroendocrine Tumor on Mortality in Patients With von Hippel-Lindau Disease. | Endocr Pract | 2021 | https://conductscience.org/library/papers/33737209 | PubMed |
| 10 | 22415670 | Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with Von Hippel-Lindau syndrome (VHL). | Pancreas | 2012 | https://conductscience.org/library/papers/22415670 | PubMed |
| 11 | 19704057 | Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19704057 | PubMed |
| 12 | 28199314 | Whole-genome landscape of pancreatic neuroendocrine tumours. | Nature | 2017 | https://conductscience.org/library/papers/28199314 | PubMed |
| 13 | 30849371 | VEGF in Signaling and Disease: Beyond Discovery and Development. | Cell | 2019 | https://conductscience.org/library/papers/30849371 | PubMed |
| 14 | 27539272 | Survival and causes of death in patients with von Hippel-Lindau disease. | J Med Genet | 2017 | https://conductscience.org/library/papers/27539272 | PubMed |
| 15 | 8730290 | Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. | J Med Genet | 1996 | https://conductscience.org/library/papers/8730290 | PubMed |
| 16 | 21386872 | von Hippel-Lindau disease: a clinical and scientific review. | Eur J Hum Genet | 2011 | https://conductscience.org/library/papers/21386872 | PubMed |
| 17 | 21306237 | Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21306237 | PubMed |
| 18 | 36358667 | Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36358667 | PubMed |
| 19 | 33616314 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33616314 | PubMed |
| 20 | 35709961 | von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. | Eur J Med Genet | 2022 | https://conductscience.org/library/papers/35709961 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39933087 | A New Era of Management of Von Hippel-Lindau Disease-Associated Tumors With Belzutifan. | Clin J Oncol Nurs | 2025 | https://conductscience.org/library/papers/39933087 | PubMed |
| 39757325 | New Developments in VHL-Associated Neuroendocrine Neoplasms. | Curr Oncol Rep | 2025 | https://conductscience.org/library/papers/39757325 | PubMed |
| 38893191 | Hereditary Syndromes Associated with Pancreatic and Lung Neuroendocrine Tumors. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38893191 | PubMed |
| 38616993 | Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review. | Diabetes Metab Syndr Obes | 2024 | https://conductscience.org/library/papers/38616993 | PubMed |
| 38180510 | [Multiple neuroendocrine tumors of the pancreas]. | Pathologie (Heidelb) | 2024 | https://conductscience.org/library/papers/38180510 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36980625
GET https://conductscience.org/api/papers/v1/36980625/references?page=2